Loading
The freshest signals in cancer: new papers, trial results, approvals and law, updated with every build.
Ranked newest first, with approvals, withdrawals and phase 3 results counting as two weeks fresher than their date, other results, law and papers in the leading journals one week fresher, and preprints one week older; every kind keeps its most recent items so no filter is empty while its source has data. Within a day the weightier items come first. Pick types to combine them; For you narrows to the cancer chosen in For me (a choice that stays in this browser); the first filter reads the full 500-item feed.
200 items on this page.
1000 changelog entries, 1 upcoming date, 3 corrections.
openFDA has a label for "Aspirin".
EMA register: Casgevy (exagamglogene autotemcel) Authorised, 2024-02-09.
EMA register: Cystagon (mercaptamine bitartrate) Authorised, 1997-06-23.
EMA register: Entyvio (vedolizumab) Authorised, 2014-05-22.
EMA register: Libmeldy (autologous CD34+ cells encoding ARSA gene) Authorised, 2020-12-17.
EMA register: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) Authorised, 2020-08-19.
EMA register: Lynkuet (elinzanetant) Authorised, 2025-11-17.
EMA register: NeoRecormon (epoetin beta) Authorised, 1997-07-16.
EMA register: Nezglyal (leriglitazone) Authorised, 2026-09-21.
EMA register: Procysbi (mercaptamine) Authorised, 2013-09-05.
EMA register: SomaKit TOC (edotreotide) Authorised, 2016-12-08.
EMA register: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) Authorised, 2016-05-26.
EMA register: Waskyra (etuvetidigene autotemcel) Authorised, 2026-01-09.
EMA register: Xromi (hydroxycarbamide) Authorised, 2019-07-01.
EMA register: Yartemlea (Narsoplimab) Opinion under re-examination.
EMA register: Zefylti (filgrastim) Application withdrawn.
ClinicalTrials.gov overall status is TERMINATED; recorded recruiting.
ClinicalTrials.gov overall status is RECRUITING; recorded planned.
ClinicalTrials.gov overall status is RECRUITING; recorded planned.
ClinicalTrials.gov overall status is WITHDRAWN; recorded recruiting.
1000 changelog entries, 1 upcoming date, 3 corrections.
993 changelog entries, 1 upcoming date, 3 corrections.
982 changelog entries, 1 upcoming date, 33 corrections.
Posted on medRxiv on 11 October 2026; not peer reviewed; matched RNF213.
Posted on Research Square on 11 October 2026; not peer reviewed; matched CCDC6.
Posted on bioRxiv on 11 October 2026; not peer reviewed; matched CAR-T cell therapy.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Cisplatin, Rituximab and Platinum agents.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Tisagenlecleucel, CAR-T cell therapy and CD19.
Posted on Research Square on 11 October 2026; not peer reviewed; matched BIRC5 and HNRNPA2B1.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Whole-exome & whole-genome sequencing, Germline (hereditary) testing and TP53.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Small-molecule kinase inhibitors, EGFR and Erlotinib.
Posted on Research Square on 11 October 2026; not peer reviewed; matched HER2 and SET.
Posted on Research Square on 11 October 2026; not peer reviewed; matched PD-1, State and STAT1.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Pertuzumab and Trastuzumab.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Chemoprevention & risk-reducing surgery.
Posted on bioRxiv on 11 October 2026; not peer reviewed; matched Whole-exome & whole-genome sequencing.
Posted on Research Square on 11 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and EZH2.
Posted on medRxiv on 11 October 2026; not peer reviewed; matched Whole-exome & whole-genome sequencing, CCDC6 and NR4A3.
Posted on bioRxiv on 11 October 2026; not peer reviewed; matched DNA methylation profiling.
Posted on Research Square on 11 October 2026; not peer reviewed; matched State.
Posted on bioRxiv on 11 October 2026; not peer reviewed; matched Doxorubicin.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Patient-derived organoids and Immune checkpoint inhibitors.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Liquid biopsy, Folate receptor alpha and CTNNB1.
Posted on Research Square on 11 October 2026; not peer reviewed; matched MRI, Antibody-drug conjugate and Enfortumab vedotin.
Posted on Research Square on 11 October 2026; not peer reviewed; matched MYOD1 and SOX10.
Posted on PsyArXiv on 11 October 2026; not peer reviewed; matched State.
Posted on Research Square on 11 October 2026; not peer reviewed; matched RNA sequencing & expression profiling.
Posted on Research Square on 11 October 2026; not peer reviewed; matched MRI, IDH1 / IDH2 and Ki-67.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and CLTC.
Posted on bioRxiv on 11 October 2026; not peer reviewed; matched Single-cell & spatial profiling and State.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Cisplatin, Azacitidine and Decitabine + cedazuridine.
Posted on bioRxiv on 11 October 2026; not peer reviewed; matched Atlas.
Posted on Research Square on 11 October 2026; not peer reviewed; matched Everolimus, CDK4/6 inhibitors and CDK4/6.
Posted on bioRxiv on 11 October 2026; not peer reviewed; matched State.
Posted on bioRxiv on 10 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Nicheformer.
Posted on bioRxiv on 10 October 2026; not peer reviewed; matched Clofarabine.
Posted on bioRxiv on 10 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and TNFRSF10B.
969 changelog entries, 1 upcoming date, 30 corrections.
Posted on Research Square on 9 October 2026; not peer reviewed; matched IMRT / IGRT, MR-guided adaptive radiotherapy and Adaptive radiotherapy.
Posted on Research Square on 9 October 2026; not peer reviewed; matched Sorafenib, Anti-angiogenic therapy and Panobinostat.
Posted on medRxiv on 9 October 2026; not peer reviewed; matched HER2, CCDC6 and SET.
Posted on bioRxiv on 9 October 2026; not peer reviewed; matched Degarelix and ELL.
Posted on bioRxiv on 9 October 2026; not peer reviewed; matched DNA methylation profiling and CCDC6.
Posted on Research Square on 9 October 2026; not peer reviewed; matched MRI and SET.
Published in Nat Rev Clin Oncol on 8 October 2026; matched the OnCo record for Trastuzumab deruxtecan.
950 changelog entries, 1 upcoming date, 30 corrections.
Published in Urol Oncol on 3 October 2026; found by the roadmap watch for A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.
Published on 3 October 2026 after first appearing as a preprint; matched MRI, DNA methylation profiling and Platinum agents.
Published on 3 October 2026 after first appearing as a preprint; matched CCDC6.
Published on 3 October 2026 after first appearing as a preprint; matched Nintedanib, Immune checkpoint inhibitors and CCDC6.
Published on 3 October 2026 after first appearing as a preprint; matched Oncolytic viruses and Mathematical models of cancer.
On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
Published on 2 October 2026 after first appearing as a preprint; matched CCDC6.
Published on 2 October 2026 after first appearing as a preprint; matched Pertuzumab, RNA sequencing & expression profiling and Single-cell & spatial profiling.
Published on 2 October 2026 after first appearing as a preprint; matched CCDC6.
Published on 2 October 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing and RNA sequencing & expression profiling.
Published on 2 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, CAR-T cell therapy and State.
Published in Nat Rev Clin Oncol on 1 October 2026; matched the OnCo record for Enfortumab vedotin.
Published in Nat Rev Clin Oncol on 1 October 2026; matched the OnCo record for Primary CNS lymphoma.
Published in Zhonghua Yi Xue Yi Chuan Xue Za Zhi on 1 October 2026; matched the OnCo record for RPS19.
Published on 1 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics.
Published on 1 October 2026 after first appearing as a preprint; matched Atlas, PTEN and MAPK1.
Published in Lancet Child Adolesc Health on 1 October 2026; matched the OnCo record for Logic-gated therapeutics.
Published in Clin Nephrol on 1 October 2026; matched the OnCo record for ATP7B.
Published in Eur Thyroid J on 1 October 2026; matched the OnCo record for DICER1.
Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Sintilimab.
Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for INHBB.
Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Claudin 18.2.
Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Pleural mesothelioma.
Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Sentinel lymph node biopsy.
Published on 1 October 2026 after first appearing as a preprint; matched Rebuilding the immune system after treatment and Chronic graft-versus-host disease.
Published in Acta Physiol (Oxf) on 1 October 2026; matched the OnCo record for MPEG1.
Published on 1 October 2026 after first appearing as a preprint; matched CCDC6 and Interleukin-10.
Published in Int J Clin Pharmacol Ther on 1 October 2026; matched the OnCo record for AFF1.
Published in Liver Int on 1 October 2026; matched the OnCo record for TBK1.
Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Spatial transcriptomics.
Published on 1 October 2026 after first appearing as a preprint; matched CCDC6.
Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for In-room imaging for radiotherapy.
Published in Protein Sci on 1 October 2026; matched the OnCo record for CTAG1B.
Published in Liver Int on 1 October 2026; matched the OnCo record for FOLFIRI.
Published in Pharmacol Res Perspect on 1 October 2026; matched the OnCo record for Cytarabine.
Published in Glia on 1 October 2026; matched the OnCo record for CX3CL1.
Published on 1 October 2026 after first appearing as a preprint; matched KRAS.
Published on 1 October 2026 after first appearing as a preprint; matched Immune checkpoint inhibitors and PD-1.
Published on 1 October 2026 after first appearing as a preprint; matched CCDC6.
Published in Pak J Pharm Sci on 1 October 2026; matched the OnCo record for Nilotinib.
Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Inflammatory myofibroblastic tumour.
Published in Neuropathology on 1 October 2026; matched the OnCo record for Primary CNS lymphoma.
Published on 1 October 2026 after first appearing as a preprint; matched PET/CT, FDG PET and AI trial matching & clinical decision support.
Published in Protein Sci on 1 October 2026; matched the OnCo record for PSPC1.
Published in J Biochem Mol Toxicol on 1 October 2026; matched the OnCo record for CCNE1.
Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for Gamma Knife.
Published in Cancer on 1 October 2026; found by the roadmap watch for ARCHES.
Published on 1 October 2026 after first appearing as a preprint; matched Med-Gemini and MedLM and CCDC6.
Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for VDR.
Published in Aust N Z J Obstet Gynaecol on 1 October 2026; matched the OnCo record for Progestins.
Published in Urol Oncol on 1 October 2026; matched the OnCo record for Multiparametric prostate MRI.
Published in Clin Transl Sci on 1 October 2026; matched the OnCo record for Fruquintinib.
Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and TNFRSF10B.
Published in Int J Med Robot on 1 October 2026; matched the OnCo record for Luminal androgen receptor triple-negative breast cancer.
Published in Pharmacol Res Perspect on 1 October 2026; matched the OnCo record for RB1.
Published in Microbiologyopen on 1 October 2026; matched the OnCo record for MT-CO1.
Published on 1 October 2026 after first appearing as a preprint; matched PD-1, Histone deacetylases and HDAC4.
Published in J Immunother on 1 October 2026; matched the OnCo record for Tocilizumab.
Published in Cancer on 1 October 2026; matched the OnCo record for Advanced-stage classical Hodgkin lymphoma.
Published in Liver Int on 1 October 2026; matched the OnCo record for EP300.
Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and COL2A1.
Published in Dis Mon on 1 October 2026; matched the OnCo record for Pancreatic neuroendocrine tumours.
Published in J Cachexia Sarcopenia Muscle on 1 October 2026; matched the OnCo record for CT body composition and sarcopenia measurement.
Published in Biosci Rep on 1 October 2026; matched the OnCo record for SNCAIP.
Published in CPT Pharmacometrics Syst Pharmacol on 1 October 2026; matched the OnCo record for Trastuzumab deruxtecan.
Published on 1 October 2026 after first appearing as a preprint; matched EZH2 and STAT1.
Published on 1 October 2026 after first appearing as a preprint; matched HIF-1α.
Published in Basic Clin Pharmacol Toxicol on 1 October 2026; matched the OnCo record for FOXO1.
Published in Clin Plast Surg on 1 October 2026; matched the OnCo record for Propranolol.
Published in Anim Genet on 1 October 2026; matched the OnCo record for SOX9.
Published on 1 October 2026 after first appearing as a preprint; matched LPA.
Published on 1 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics, Epigenetic age after cancer treatment and Telomere length after treatment.
Published in Neuropathol Appl Neurobiol on 1 October 2026; matched the OnCo record for SMARCB1.
Published in Neuropathology on 1 October 2026; matched the OnCo record for CIC.
Published in J Immunother on 1 October 2026; matched the OnCo record for Extensive-stage small-cell lung cancer.
Published in Cancer on 1 October 2026; matched the OnCo record for TET2.
Published in J Cachexia Sarcopenia Muscle on 1 October 2026; matched the OnCo record for REST.
Published in Hematol Oncol Clin North Am on 1 October 2026; matched the OnCo record for Gastrointestinal stromal tumour.
Published in Glia on 1 October 2026; matched the OnCo record for AXL.
Published in Pancreas on 1 October 2026; matched the OnCo record for Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.
Published in Neuropathology on 1 October 2026; matched the OnCo record for DICER1.
Published in Cancer Cytopathol on 1 October 2026; matched the OnCo record for Mucoepidermoid carcinoma.
Published on 1 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics, Atlas and State.
Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, DNA methylation profiling and PAX6.
Published in Int J Dev Neurosci on 1 October 2026; matched the OnCo record for Gamma-secretase.
Published in J Med Primatol on 1 October 2026; matched the OnCo record for Medullary thyroid cancer.
Published on 1 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.
Published in Pak J Pharm Sci on 1 October 2026; matched the OnCo record for Capecitabine.
Published in Biomed Chromatogr on 1 October 2026; matched the OnCo record for Ceralasertib.
Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Salivary duct carcinoma.
Published in J Pept Sci on 1 October 2026; matched the OnCo record for Mia.
Published on 1 October 2026 after first appearing as a preprint; matched Pertuzumab and PLK1.
Published on 1 October 2026 after first appearing as a preprint; matched CCDC6.
Published in J Immunother on 1 October 2026; matched the OnCo record for Talimogene laherparepvec.
Published in J Clin Oncol on 25 September 2026; found by the roadmap watch for STELLAR.
On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Accelerated approval (Etcamah) The confirmatory requirement was still open 0.0 years later, when the FDA's table was read.
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Withdrawn: the indication came off the label 2.3 years after its accelerated approval.
NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.
On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
FDA clearance: first digital-pathology-based risk stratification tool for early HR+/HER2- breast cancer.
On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Withdrawn: the indication came off the label 6.4 years after its accelerated approval.
Withdrawn: the indication came off the label 6.0 years after its accelerated approval.
Withdrawn: the indication came off the label 5.9 years after its accelerated approval.
Programme deprioritised after regulatory feedback on Duravelo-2 design.
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).
Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.
Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.
Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.
Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.
Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.
Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.
Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.
Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.
Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).
Co-primary endpoints including OS met (July 2026); numbers pending.
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
Stopped early; primary endpoint not met.
Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).
Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.
Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).
A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.
Everything above is read at build time from snapshots and records already in the repository; nothing is fetched when the page is viewed. Where each kind comes from and how often its source refreshes, from the workflow schedules in .github/workflows:
FDA Oncology Center of Excellence approval notifications (public/fda/recent.json), dated approvals recorded on product pages, and European Commission authorisations from the regional approvals table with an EPAR or regulator link.
Refresh: FDA feed Wednesdays 06:07 UTC (refresh-fda.yml); EU rows checked against the EMA register Wednesdays 06:37 UTC (refresh-regional.yml); product pages by hand.
Dated withdrawals recorded on product pages and withdrawn EU authorisations in the regional approvals table, each with a source link.
Refresh: Same schedule as approvals.
Trials in the corpus with a reported year and structured outcomes, linked to the primary paper, sponsor release or registry entry the outcome cites.
Refresh: Curated by hand; ClinicalTrials.gov status refreshed Mondays 06:17 UTC (refresh-trials.yml).
The newest Europe PMC matches for every product, target, cancer and technology (public/papers), journal versions of tracked preprints, and papers the roadmap watch found for landmark trials. One entry per DOI, however many records it matched.
Refresh: Literature snapshot Tuesdays 05:41 UTC (refresh-papers.yml); roadmap watch Thursdays 05:29 UTC (roadmap-watch.yml).
bioRxiv, medRxiv, Research Square and other preprints of the last 90 days that match a target, product or technology query (public/preprints). Not peer reviewed.
Refresh: Wednesdays 06:17 UTC (refresh-preprints.yml).
Statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made, each linked to its primary text.
Refresh: Curated by hand; new instruments are added when they are enacted.
Changes the nightly bot proposes for the corpus from the FDA feed, the EMA register and registry status changes (public/proposals/latest.json). Proposals, not facts: each waits for a human to apply it.
Refresh: Daily 03:23 UTC (propose.yml).
OnCo's own weekly issue: what changed, regulatory events, upcoming readouts and what the journals published.
Refresh: Mondays 07:31 UTC (newsletter.yml); the archive is rebuilt with every deploy.
Dates are shown at the precision the source gives: a year-only law or authorisation is grouped under its year, never given a day. Papers are matched to records by their literature queries, so a code or a common word can pull in an unrelated paper; the record chips tell you what matched. Not medical advice.